Home › Funds › Hikari Power Ltd › CRVS
Hikari Power Ltd position in CRVS
CORVUS PHARMACEUTICALS INC · Health Care
Hikari Power Ltd reported holding 49,959 shares of CRVS (CORVUS PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$576K, representing 0.13% of its reported portfolio and ranking #24 among its reported holdings. Hikari Power Ltd has disclosed CRVS holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How Hikari Power Ltd's CRVS position evolved
Hikari Power Ltd first disclosed a stake in CRVS in Q3 2023 at 49,959 shares (US$73K). The position peaked in Q2 2026 at 49,959 shares, worth US$746K. Across 13 filings, Hikari Power Ltd held the position steady without any share-count change. The most recent filing (Q3 2026) shows 49,959 shares valued at US$576K.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 49.96K | $73.00K | New |
| Q4 2023 | 49.96K | $88.00K | Hold |
| Q1 2024 | 49.96K | $89.00K | Hold |
| Q2 2024 | 49.96K | $91.00K | Hold |
| Q3 2024 | 49.96K | $264.00K | Hold |
| Q4 2024 | 49.96K | $267.00K | Hold |
| Q1 2025 | 49.96K | $159.00K | Hold |
| Q2 2025 | 49.96K | $200.00K | Hold |
| Q3 2025 | 49.96K | $368.00K | Hold |
| Q4 2025 | 49.96K | $385.00K | Hold |
| Q1 2026 | 49.96K | $731.00K | Hold |
| Q2 2026 | 49.96K | $746.00K | Hold |
| Q3 2026 | 49.96K | $576.00K | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About CRVS and 13F data
CRVS (CORVUS PHARMACEUTICALS INC) is a Health Care company. 67 other funds we track also report a position in CRVS — the largest reported positions include ORBIMED ADVISORS LLC (US$107.0M), ADAMS STREET PARTNERS LLC (US$48.9M), PERCEPTIVE ADVISORS LLC (US$39.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding CRVS
- ORBIMED ADVISORS LLC 7.17M sh · $107.05M · Q2 2026
- ADAMS STREET PARTNERS LLC 3.28M sh · $48.94M · Q2 2026
- PERCEPTIVE ADVISORS LLC 2.67M sh · $39.85M · Q2 2026
- Deep Track Capital, LP 2.49M sh · $37.23M · Q2 2026
- Vivo Capital, LLC 2.81M sh · $32.32M · Q3 2026
- BRAIDWELL LP 2.13M sh · $31.77M · Q2 2026
- Foresite Capital Management VI LLC 1.83M sh · $27.36M · Q2 2026
- Boxer Capital Management, LLC 1.10M sh · $16.43M · Q2 2026
- Catalio Capital Management, LP 1.08M sh · $16.15M · Q2 2026
- Eversept Partners, LP 747.99K sh · $11.18M · Q2 2026
- DCF Advisers, LLC 641.50K sh · $7.39M · Q3 2026
- Nextech Invest Ltd. 450.00K sh · $6.72M · Q2 2026
More on Hikari Power Ltd
FAQ
How long has Hikari Power Ltd held CRVS?
Hikari Power Ltd has disclosed CRVS holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is Hikari Power Ltd's current position in CRVS?
As of Q3 2026, Hikari Power Ltd holds 49.96K shares of CRVS (CORVUS PHARMACEUTICALS INC), valued at $576.00K, representing 0.13% of its reported portfolio and ranking #24.
Has Hikari Power Ltd been buying or selling CRVS?
In the latest 13F filing (Q3 2026), Hikari Power Ltd held unchanged its position in CRVS. The position peaked in Q2 2026 at 49.96K shares.
Which other funds hold CRVS?
Other major institutional holders of CRVS include ORBIMED ADVISORS LLC, ADAMS STREET PARTNERS LLC, PERCEPTIVE ADVISORS LLC, among 67 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.